Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury (FAIRTOP II)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01270659|
Recruitment Status : Completed
First Posted : January 5, 2011
Results First Posted : June 20, 2017
Last Update Posted : June 20, 2017
|Condition or disease||Intervention/treatment||Phase|
|Pain||Drug: Fentanyl Drug: Oxycodone/acetaminophen Drug: oxycodone/acetaminophen||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Supportive Care|
|Official Title:||Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain: The FAIRTOP II Trial|
|Study Start Date :||May 2011|
|Actual Primary Completion Date :||October 2014|
|Actual Study Completion Date :||October 2014|
Subject will receive FBT and placebo at a low dose
Fentanyl buccal tablet 100 mcg once
Other Name: Fentora 100 mcg buccal tablet
Subject will receive the high dose regimen of FBT and a high dose placebo
Fentanyl buccal tablet 200 mcg once
Other Name: Fentora buccal tablet 200 mcg
Active Comparator: Low control
Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl "placebo"
Oxycodone/acetaminophen 5/325 mg once
Other Name: Percocet 5/325
Active Comparator: High control
Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl "placebo"
Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time
Other Name: Percocet 5/325
- Median Time to Significant Analgesia (at Least 2 Units Decrease in Pain Level) [ Time Frame: 60 minutes ]Median time (in minutes) to 2 units decrease in pain level after drug administration. Patients were asked to rate their pain at every 5 minutes intervals from 0 to 60 minutes post drug administration. The 10-point verbally administered numeric pain rating scale (NPRS) was used to have patients rate their level of pain on a scale of 0 (no pain) to 10 (worst pain ever).
- Nausea Level [ Time Frame: every 5 minutes for the first 60 minutes ]
Subjects' nausea level was recorded to determine how fentanyl buccal tablet compares to standard therapy in causing nausea. Treatment induced nausea and severity of nausea level was assessed.
Nausea was assessed by a 10-point verbally administered scale. Patients rated their degree of nausea on a scale of 0 (no nausea) to 10 (worst nausea).
At the beginning of the study, literature review found relatively little evidence guiding objective means to rate nausea, but there was some precedent for this approach (Warden C. Prehospital use of ondansetron reduces nausea and episodes of vomiting in adults and children over 12 years old [abstract]. Prehosp Emerg Care. 2007;11:132).
- Number of Participants Experiencing Any Adverse Events [ Time Frame: Full 2 hours of the study period ]Occurrence of any adverse event.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01270659
|United States, Oklahoma|
|Hillcrest Medical Center Emergency Department|
|Tulsa, Oklahoma, United States, 74104|
|Principal Investigator:||Stephen H Thomas, MD MPH||University of Oklahoma|
|Study Director:||Annette O Arthur, PharmD||University of Oklahoma|